After a dosing arm of a trial - normally a pharma doesn't need to go running to the FDA to move into the selected dose (even the trial protocol says that) - unless the FDA may have a problem with what you want to do.
Just saying.
Learn FDA protocol. And stop saying the drug impacts DNA because some non-medico private citizen of Otago, New Zealand said it in a discussion paper.
My conclusions are founded in a more robust inquiry.
Where we at?, page-691
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $103.1M | |||
| Open | High | Low | Value | Volume |
| 29.0¢ | 29.5¢ | 28.5¢ | $11.35K | 39.04K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 2361 | 28.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 29.0¢ | 78695 | 3 |
View Market Depth
| Last trade - 11.57am 09/07/2024 (20 minute delay) ? |
| PAR (ASX) Chart |